Rockefeller Capital Management
CATX icon

Rockefeller Capital Management’s Perspective Therapeutics CATX Stock Holding History

Rockefeller Capital Management’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,000
Closed -$12.5K – 4750
2026
Q1 		$12.5K Hold
3,000
– – ﹤0.01% 3900
2025
Q4 		$8.25K Hold
3,000
– – ﹤0.01% 3891
2025
Q3 		$10.3K Buy
+3,000
New +$10.9K ﹤0.01% 3632

Other funds holding CATX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Rockefeller Capital Management's CATX Position: Q2 2026 in Review

Rockefeller Capital Management sold out of Perspective Therapeutics (CATX) in Q2 2026, closing a stake of 3,000 shares — an estimated $12.5K sold.

Rockefeller Capital Management first reported a position in CATX in Q3 2025 and held it in 3 quarters. The position peaked at $12.5K in Q1 2026. 131 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

  • Rockefeller Capital Management reported no remaining Perspective Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Rockefeller Capital Management sold 3,000 Perspective Therapeutics shares in Q2 2026, an estimated $12.5K.
  • Rockefeller Capital Management first reported a position in Perspective Therapeutics in Q3 2025 and held it in 3 quarters.
  • Rockefeller Capital Management's Perspective Therapeutics position peaked at $12.5K in Q1 2026.
  • 131 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.